Moderna, Inc.
MRNA
$35.61
$1.313.82%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -53.40% | -43.18% | -51.48% | -65.06% | -63.81% |
| Total Other Revenue | -28.25% | -69.53% | -73.10% | -80.17% | -78.62% |
| Total Revenue | -52.75% | -44.29% | -52.60% | -65.78% | -64.45% |
| Cost of Revenue | -37.02% | -37.27% | -7.00% | -3.19% | 9.49% |
| Gross Profit | -3.01% | -15.61% | -276.43% | -160.39% | -125.49% |
| SG&A Expenses | -24.21% | -11.07% | 12.71% | 29.85% | 36.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -35.23% | -34.04% | -4.50% | 0.59% | 12.64% |
| Operating Income | 6.94% | -1.05% | -1,003.51% | -206.46% | -145.00% |
| Income Before Tax | 8.50% | 0.17% | -629.58% | -195.26% | -141.17% |
| Income Tax Expenses | -105.96% | -111.63% | 494.60% | 353.70% | -36.36% |
| Earnings from Continuing Operations | 24.46% | 35.83% | -586.08% | -224.75% | -156.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.46% | 35.83% | -586.08% | -224.75% | -156.37% |
| EBIT | 6.94% | -1.05% | -1,003.51% | -206.46% | -145.00% |
| EBITDA | -3.81% | -9.05% | -568.84% | -188.13% | -137.04% |
| EPS Basic | 25.00% | 36.51% | -601.73% | -227.99% | -158.58% |
| Normalized Basic EPS | 8.80% | 2.04% | -631.06% | -195.82% | -141.87% |
| EPS Diluted | 25.16% | 37.42% | -662.79% | -235.26% | -162.14% |
| Normalized Diluted EPS | 8.55% | 4.67% | -737.43% | -201.27% | -144.17% |
| Average Basic Shares Outstanding | 0.46% | -0.07% | -0.91% | -2.06% | -2.80% |
| Average Diluted Shares Outstanding | -0.77% | -0.76% | -3.81% | -6.22% | -6.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
